RPG Life Sciences Ltd reports Q2 FY27 revenue of ₹211.6 crore, up 16.5% year on year
- Adjusted EBITDA rose 15.0% to ₹50.1 crore; adjusted EBITDA margin was 23.7%, versus 24.0% a year earlier.
- Reported EBITDA was ₹44.7 crore after ₹5.5 crore in one-off API acquisition and restructuring costs.
- Gross margin expanded 260 basis points.